Alvocidib Biomarker-driven Phase 2 AML Study
Phase 2 Terminated
104 enrolled 12 charts
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Phase 1 Completed
32 enrolled 15 charts
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Phase 2 Terminated
11 enrolled 10 charts
AML
Phase 1 Completed
10 enrolled
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
Phase 1/2 Withdrawn
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
78 enrolled 10 charts
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
172 enrolled 12 charts
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
45 enrolled 7 charts
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Completed
92 enrolled 10 charts
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
Phase 1/2 Completed
53 enrolled
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
Phase 1 Completed
35 enrolled
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Terminated
88 enrolled
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
Phase 1 Completed
24 enrolled